NYS HCV Care Provider Directory
Dear HCV Provider,
As you may be aware, in early 2015, the NYSDOH AIDS Institute launched a web-based public directory of experienced HIV care practitioners in New York State. We are excited to announce this directory has now been expanded to include experienced HCV care practitioners. We encourage all HCV practitioners in New York State to register for the purpose of providing the public with information about where patients living with HCV can access experienced providers within the State.
Participation in this directory is voluntary. It is compiled through provider self-identification, and includes physicians, nurse practitioners, physician assistants, and doctors of osteopathic medicine with experience in HCV care and treatment and who meet the NYSDOH definition of an experienced HCV provider. Please note that this list in no way constitutes credentialing or certification in a specialty. Inclusion in this list does not confer any endorsement by the New York State Department of Health. We confirm that practitioners are licensed to practice in New York State.
If you are interested in being listed in this directory, please follow the steps outlined below to register through our on-line registration system. We will email you annual reminders to confirm/update your contact information. You are able to withdraw your name from this directory at any time. If you already participate in the directory as an HIV provider and would also like to register as an HCV provider, simply log into HCS and update your record with your HCV-related information.
To register: First you must log on to the NYSDOH Health Commerce System (HCS). If you do not already have an account or need help accessing your HCS account, please send an email to email@example.com.
Step 1: Log on to HCS at https://commerce.health.state.ny.us.
Step 2: Click ‘My Content’ -> ‘All Applications’.
Step 3: Click letter ‘H’ and select ‘HIV/HCV Provider Directory’.
Step 4: Follow the instructions as provided on the screen. Step 5: Email firstname.lastname@example.org with any questions or concerns.
The public listing of the directory will include providers’ names, contact information, and credentials as an HIV and/or HCV specialist (if applicable). This directory will be made available to the public online and will be updated at the beginning of each month.
Finally, please forward this invitation to any HCV or HIV care provider who may be interested in registering themselves in the directory. We thank you for your time and wish you all the best.
AIDS Institute, Viral Hepatitis Section
For Care Providers
- E-patients.net: Salzburg Statement on Shared Decision Making
- New York State Department of Health (NYS DOH):
- CEI: HIV, HCV & STD Clinical Education Initiative
- CEI: HCV Clinical Cards (to attach to name badges; available for NYS care providers)
- Communicable Disease Reporting Requirements
- Directory of ESAP Providers in New York State
- Hepatitis C
- NYS AIDS Institute Training Center
- Office of Alcoholism and Substance Abuse Services
- Office of Mental Health
- U.S. Department of Labor Occupational Safety and Health Administration (OSHA):
- University of Washington: Hepatitis C Online
- NYS DOH/New York City Department of Health and Mental Hygiene (NYC DOHMH) Patient Education Material: These message pads are designed for persons performing HCV screening/counseling to ensure that counseling messages appropriate for specific screening test results are delivered.
- AASLD/IDSA: HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
- U.S. Department of Veterans Affairs: Viral Hepatitis Guidelines and Best Practices
- MCN: Migrant Clinicians Network
- National Institutes of Health (NIH): ClinicalTrials.gov
- New York eHealth Collaborative: NYEC
- New York State (NYS):
- NYS DOH:
- AIDS Institute Provider Directory (HIV, HCV, PEP, PrEP)
- Directory of ESAP Providers in New York State
- Expanded Syringe Access Program (ESAP): Overview of Law and Regulations
- HCV Rapid Testing Program
- Hepatitis C
- NYS Safe Sharps Collection Program
- Office of Alcoholism and Substance Abuse Services
- Office of Mental Health
- Wadsworth Center
- Alcohol and Drug Use Screening Tools:
- Classifying the Severity of Cirrhosis:
- NYS DOH: CEI: HIV, HCV & STD Clinical Education Initiative
- Treatment Readiness Evaluation: Psychosocial Readiness Evaluation and Preparation for HCV Treatment (PREP-C)
- Centers for Disease Control and Prevention (CDC):
- National Institutes of Health (NIH): ClinicalTrials.gov
- New York State Department of Health (NYS DOH)
- Treatment Action Group (TAG): HCV Fact Sheets in English and en Español
Consumer Q/A: Treatment of Hep C with DAAs
The New York State Department of Health AIDS Institute has released a new guideline about treating Hepatitis C. This Q/A fact sheet covers the topics in the guideline and can help people talk with their healthcare providers about Hep C.
About the Guideline
What is the purpose of the guideline? The guideline is a set of recommendations for healthcare providers. It explains how treat Hep C using the new direct-acting antiviral drugs. “Direct-acting antiviral” is abbreviated as “DAA.” On average, DAAs cure Hep C in 90% or more of the people who take them.
Who wrote the guideline? The guideline was written by a group of doctors in New York who specialize in treating Hep C and liver disease. It was also reviewed by people living with Hep C. The recommendations are based on research studies and the doctors’ experience treating patients.
About Hep C
What is Hep C? Hep C is a virus that infects the liver. Most people do not have symptoms for many years.
Over time, Hep C can cause the liver to thicken and scar. This scarring is called “fibrosis.” As the scarring becomes worse, the liver does not function correctly. The late stage of scarring is called “cirrhosis.” Cirrhosis can lead to life-threatening liver failure or liver cancer.
Treatment with direct-actiing antivirals (called “DAAs”) can cure Hep C, and cure can prevent or slow down liver damage.
How is Hep C spread? Hep C is spread when the blood of a person who has the virus enters the body of a person who does not have the virus. Hep C is not spread through casual contact, such as sneezing, hugging, or sharing eating or drinking utensils.
Who should get tested for Hep C? If you can answer “Yes” to any question below, you should get a test.
- Were you born between 1945 and 1965? This group, the “baby-boomers,” may have been infected during the 1970s and 1980s, before the Hep C virus was discovered. Hep C testing is recommended for all people in this age group
- Do you have HIV infection?
- Did you have a blood transfusion or organ transplant before 1992?
- Has a healthcare provider ever told you that you have abnormal liver tests or liver disease?
- Do you get long term kidney dialysis?
- Have you ever been in jail or prison?
- Have you ever shared drug injection equipment? Even once?
- Have you engaged in any type of high-risk sex? For instance, have you ever been the bottom during anal sex? Had sex after using methamphetamine (crystal meth, crystal, crank, ice) or other drugs? Had multiple sex partners?
- Have you been diagnosed with a sexually transmitted infection, like syphilis, gonorrhea, or herpes, in the past year?
- Have you ever gotten a tattoo, piercing, or acupuncture in a place that did not seem clean?
- Are you a healthcare worker who has ever been stuck by a needle or splashed by blood from a patient?
- Has your mother had a positive Hep C test?
If you think you might have been exposed to Hep C but are not sure, then you should get tested. For more information, visit: Should You Be Tested for Hep C?
Diagnosing Hep C
How is Hep C diagnosed? Hepatitis C diagnosis requires two tests: an antibody test and an RNA test. Both tests require a blood sample.
1. Antibody test: Hepatitis C antibodies form in your blood when you have been exposed to the virus. If the antibody test is negative, then you don’t have Hep C infection. If you have engaged in risky behavior in the past 6 months, you should be tested again.
A positive Hep C antibody test by itself does not mean that you have Hep C. It means you have been exposed and might have chronic Hep C. You need an RNA test to confirm the diagnosis.
If you have been treated for Hep C and cured in the past, your antibody test will be positive.
2. RNA test: An RNA test measures the amount of Hep C virus in your blood. If the RNA test finds Hep C virus in your blood, then you have active Hep C infection. If Hep C virus is not detected, then you do not have active Hep C infection.
If you do have Hep C, you should talk with your healthcare provider about treatment.
Treating Hep C
What does your healthcare provider need to know before giving you treatment? A healthcare provider needs to know about your health history and current health. She or he will ask you questions, examine you, and perform tests to help decide which medications are best for you.
What are DAAs? DAAs are pills that combine more than one medication that works directly against the hepatitis C virus to treat it. Treatment usually lasts for 12 weeks (3 months) to 24 weeks (6 months). Different combinations of DAAs work best for different people. Some people take DAAs with another drug called ribavirin.
How will your healthcare provider pick the DAA combination for you? You and your healthcare provider will work together to decide the best treatment for you. The specifics of your situation will guide the choice, such as:
- Your Hep C genotype. Different strains of the virus are called “genotypes.” Genotype 1 is the most common in the United States.
- Whether you were treated for Hep C before.
- Whether you have liver damage. A simple blood test can determine if you have liver damage. A liver biopsy is no longer required.
- Other medications you are taking.
- The number of pills you are comfortable taking.
- Whether you are pregnant or trying to get pregnant.
- Whether your partner is trying to get pregnant.
- Your health insurance: Almost all types of health insurance cover the DAAs, but not all companies cover all of the DAAs. Your healthcare provider will find out what your company covers. If you don’t have health insurance, your healthcare provider can help you find payment assistance programs.
Do DAAs have side effects? Most people don’t get side effects when they take DAAs. Some people have experienced tiredness, diarrhea, headache, trouble sleeping, and stomach upset. If you take DAAs and feel any side effects, tell your healthcare provider.
How will you know if you are cured? Your healthcare provider will perform an HCV RNA follow-up test 12 weeks (3 months) after you finish treatment. If the test does not detect Hep C virus in your blood, you are cured of Hep C infection. If there is still Hep C virus in your blood, you are not cured.
If you are not cured, then a different combination of DAAs might work for you.
Preventing Hep C After Treatment
Can you get Hep C again after you are cured? Yes. Being treated for and cured of Hep C infection does not protect you from getting it again. To protect yourself from being infected with Hep C again, do not share needles, syringes or drug use equipment, personal items like toothbrushes or razors and use condoms.
GOALS Framework for Sexual History Taking in Primary Care
Developed by Sarit A. Golub, PhD, MPH, Hunter College and Graduate Center, City University of New York, in collaboration with the NYC Department of Health and Mental Hygiene, Bureau of HIV, July 2019
Background: Sexual history taking can be an onerous and awkward task that does not always provide accurate or useful information for patient care. Standard risk assessment questions (e.g., How many partners have you had sex with in the last 6 months?; How many times did you have receptive anal sex with a man when he did not use a condom?) may be alienating to patients, discourage honest disclosure, and communicate that the number of partners or acts is the only component of sexual risk and health.
In contrast, the GOALS framework is designed to streamline sexual history conversations and elicit information most useful for identifying an appropriate clinical course of action.
The GOALS framework was developed in response to 4 key findings from the sexual health research literature:
- Universal HIV/STI screening and biomedical prevention education is more beneficial and cost-effective than risk-based screening [Wimberly, et al. 2006; Hoots, et al. 2016; Owusu-Edusei, et al. 2016; Hull, et al. 2017; Lancki, et al. 2018].
- Emphasizing benefits—rather than risks—is more successful in motivating patients toward prevention and care behavior [Weinstein and Klein 1995; Schuz, et al. 2013; Sheeran, et al. 2014].
- Positive interactions with healthcare providers promote engagement in prevention and care [Bakken, et al. 2000; Alexander, et al. 2012; Flickinger, et al. 2013].
- Patients want their healthcare providers to talk with them about sexual health [Marwick 1999; Ryan, et al. 2018].
Rather than seeing sexual history taking as a means to an end, the GOALS framework considers the sexual history taking process as an intervention that will:
- Increase rates of routine HIV/STI screening;
- Increase rates of universal biomedical prevention and contraceptive education;
- Increase patients’ motivation for and commitment to sexual health behavior; and
- Enhance the patient-care provider relationship, making it a lever for sexual health specifically and overall health and wellness in general.
The GOALS framework includes 5 steps:
- Give a preamble that emphasizes sexual health. The healthcare provider briefly introduces the sexual history in a way that de-emphasizes a focus on risk, normalizes sexuality as part of routine healthcare, and opens the door for the patient’s questions.
- Offer opt-out HIV/STI testing and information. The healthcare provider tells the patient that they test everyone for HIV and STIs, normalizing both testing and HIV and STI concerns.
- Ask an open-ended question. The healthcare provider starts the sexual history taking with an open-ended question that allows them to identify the aspects of sexual health that are most important to the patient, while allowing them to hear (and then mirror) the language that the patient uses to describe their body, partner(s), and sexual behaviors.
- Listen for relevant information and fill in the blanks. The healthcare provider asks more pointed questions to elicit information that might be needed for clinical decision-making (e.g., 3-site versus genital-only testing), but these questions are restricted to specific, necessary information. For instance, if a patient has already disclosed that he is a gay man with more than 1 partner, there is no need to ask about the total number of partners or their HIV status in order to recommend STI/HIV testing and PrEP education.
- Suggest a course of action. Consistent with opt-out testing, the healthcare provider offers all patients HIV testing, 3-site STI testing, PrEP education, and contraceptive counseling, unless any of this testing is specifically contraindicated by the sexual history. Rather than focusing on any risk behaviors the patient may be engaging in, this step focuses specifically on the benefits of engaging in prevention behaviors, such as exerting greater control over one’s sex life and sexual health and decreasing anxiety about potential transmission.
Resources for implementation:
- Script, rationale, and goals: Box 1, below, provides a suggested script for each step in the GOALS framework, along with the specific rationale for that step and the goal it is designed to accomplish.
- The 5Ps model for sexual history-taking (CDC): Note that the GOALS framework is not designed to completely replace the 5Ps model (partners, practices, protection from STI, past history of STI, prevention of pregnancy); instead, it provides a framework for identifying information related to the 5Ps that improves patient-care provider communication, reduces the likelihood of bias or missed opportunities, and enhances patients’ motivation for prevention and sexual health behavior.
|Box 1: GOALS Framework for the Sexual History [download chart PDF]|
|Component||Suggested Script||Rationale and Goal Accomplished|
|Give a preamble that emphasizes sexual health.||I’d like to talk with you for a couple of minutes about your sexuality and sexual health. I talk to all of my patients about sexual health, because it’s such an important part of overall health. Some of my patients have questions or concerns about their sexual health, so I want to make sure I understand what your questions or concerns might be and provide whatever information or other help you might need.||
|Offer opt-out HIV/STI testing and information.||First, I like to test all my patients for HIV and other sexually transmitted infections. Do you have any concerns about that?||
|Ask an open-ended question.||
Pick one (or use an open-ended question that you prefer):
|Listen for relevant information and probe to fill in the blanks.||
|Suggest a course of action.||
Alexander JA, Hearld LR, Mittler JN, et al. Patient-physician role relationships and patient activation among individuals with chronic illness. Health Serv Res 2012;47(3 Pt 1):1201-1223. [PMID: 22098418]
Bakken S, Holzemer WL, Brown MA, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS 2000;14(4):189-197. [PMID: 10806637]
Flickinger TE, Saha S, Moore RD, et al. Higher quality communication and relationships are associated with improved patient engagement in HIV care. J Acquir Immune Defic Syndr 2013;63(3):362-366. [PMID: 23591637]
Hoots BE, Finlayson T, Nerlander L, et al. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men-20 US cities, 2014. Clin Infect Dis 2016;63(5):672-677. [PMID: 27282710]
Hull S, Kelley S, Clarke JL. Sexually transmitted infections: Compelling case for an improved screening strategy. Popul Health Manag 2017;20(S1):S1-S11. [PMID: 28920768]
Lancki N, Almirol E, Alon L, et al. Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago. AIDS 2018;32(3):383-392. [PMID: 29194116]
Marwick C. Survey says patients expect little physician help on sex. JAMA 1999;281(23):2173-2174. [PMID: 10376552]
Owusu-Edusei K, Jr., Hoover KW, Gift TL. Cost-effectiveness of opt-out chlamydia testing for high-risk young women in the U.S. Am J Prev Med 2016;51(2):216-224. [PMID: 26952078]
Ryan KL, Arbuckle-Bernstein V, Smith G, et al. Let’s talk about sex: A survey of patients’ preferences when addressing sexual health concerns in a family medicine residency program office. 2018;2. https://journals.stfm.org/primer/2018/ryan-2018-0004
Schuz N, Schuz B, Eid M. When risk communication backfires: randomized controlled trial on self-affirmation and reactance to personalized risk feedback in high-risk individuals. Health Psychol 2013;32(5):561-570. [PMID: 23646839]
Sheeran P, Harris PR, Epton T. Does heightening risk appraisals change people’s intentions and behavior? A meta-analysis of experimental studies. Psychol Bull 2014;140(2):511-543. [PMID: 23731175]
Weinstein ND, Klein WM. Resistance of personal risk perceptions to debiasing interventions. Health Psychol 1995;14(2):132-140. [PMID: 7789348]
Wimberly YH, Hogben M, Moore-Ruffin J, et al. Sexual history-taking among primary care physicians. J Natl Med Assoc 2006;98(12):1924-1929. [PMID: 17225835]